Update on Anti-angiogenic Treatment for Malignant Gliomas

被引：12
作者：
de Groot, John F. [1 ]
Mandel, Jacob J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CURRENT ONCOLOGY REPORTS | 2014年 / 16卷 / 04期
关键词：
Malignant gliomas; Brain tumor; Oncology; Neuro-oncology; Anti-angiogenic treatment; Gliomas; Treatment; BEVACIZUMAB PLUS IRINOTECAN; PHASE-II TRIAL; GLIOBLASTOMA; RECURRENT; TEMOZOLOMIDE; STRATEGIES; THERAPY; ASTROCYTOMA; PACLITAXEL; RESISTANCE;
D O I：
10.1007/s11912-014-0380-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Malignant gliomas are the most common primary brain tumor found in adults. Unfortunately, the prognosis for these type of tumors remains dismal despite aggressive treatment with surgical resection, radiation and chemotherapy. Therefore, therapeutics aimed at disrupting the angiogenesis of these tumors is being utilized in to improve survival outcomes and quality of life. This paper reviews the history of antiangiogenic agents in malignant gliomas, discusses the FDA approval of bevacizumab as monotherapy in recurrent glioblastoma and the subsequent controversy, and analyzes the most recent newly diagnosed trials of RTOG 0825 and AVAglio. Additionally, the results of the latest trials with antiangiogenic agents and possible biomarkers are reviewed. Multiple questions remain regarding the potential benefit of antiangiogenic treatments in patients with glioblastoma. Future clinical trials should be designed to learn more about these drugs, to optimize their future use.
引用
收藏
页数：7
相关论文
共 49 条
[1]   Time course of imaging changes of GBM during extended bevacizumab treatment [J].
Ananthnarayan, Suchitra ;
Bahng, Jennie ;
Roring, James ;
Nghiemphu, Phioanh ;
Lai, Albert ;
Cloughesy, Timothy ;
Pope, Whitney B. .
JOURNAL OF NEURO-ONCOLOGY, 2008, 88 (03) :339-347
[2]  
Armstrong TS, 2013, P AM SOC CLIN ONCOL
[3]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
[4]   Modes of resistance to anti-angiogenic therapy [J].
Bergers, Gabriele ;
Hanahan, Douglas .
NATURE REVIEWS CANCER, 2008, 8 (08) :592-603
[5]  
Brem S, 1972, J NEUROONCOL, V48, P347
[6]   Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography:: A pilot study [J].
Chen, Wei ;
Delaloye, Sibylle ;
Silverman, Daniel H. S. ;
Geist, Cheri ;
Czernin, Johannes ;
Sayre, James ;
Satyamurthy, Nagichettiar ;
Pope, Whitney ;
Lai, Albert ;
Phelps, Michael E. ;
Cloughesy, Timothy .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (30) :4714-4721
[7]   Antiangiogenic Strategies for Treatment of Malignant Gliomas [J].
Chi, Andrew S. ;
Norden, Andrew D. ;
Wen, Patrick Y. .
NEUROTHERAPEUTICS, 2009, 6 (03) :513-526
[8]   Angiogenesis as a Therapeutic Target in Malignant Gliomas [J].
Chi, Andrew S. ;
Sorensen, A. Gregory ;
Jain, Rakesh K. ;
Batchelor, Tracy T. .
ONCOLOGIST, 2009, 14 (06) :621-636
[9]   FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme [J].
Cohen, Martin H. ;
Shen, Yuan Li ;
Keegan, Patricia ;
Pazdur, Richard .
ONCOLOGIST, 2009, 14 (11) :1131-1138
[10]   Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice [J].
de Groot, John F. ;
Fuller, Gregory ;
Kumar, Ashok J. ;
Piao, Yuji ;
Eterovic, Karina ;
Ji, Yongjie ;
Conrad, Charles A. .
NEURO-ONCOLOGY, 2010, 12 (03) :233-242
12345